%0 Journal Article
%A Pfütze, Katrin
%A Benner, Axel
%A Hoffmeister, Michael
%A Jansen, Lina
%A Yang, Rongxi
%A Bläker, Hendrik
%A Herpel, Esther
%A Ulrich, Alexis
%A Ulrich, Cornelia M
%A Chang-Claude, Jenny
%A Brenner, Hermann
%A Burwinkel, Barbara
%T Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy.
%J Genomics
%V 106
%N 6
%@ 0888-7543
%C San Diego, Calif.
%I Academic Press
%M DKFZ-2017-03324
%P 348 - 354
%D 2015
%X DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.
%K Antimetabolites, Antineoplastic (NLM Chemicals)
%K Cell Adhesion Molecules (NLM Chemicals)
%K GPI-Linked Proteins (NLM Chemicals)
%K Hyal2 protein, human (NLM Chemicals)
%K Hyaluronoglucosaminidase (NLM Chemicals)
%K Fluorouracil (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:26453961
%R 10.1016/j.ygeno.2015.10.002
%U https://inrepo02.dkfz.de/record/127299